Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for…
Boehringer Ingelheim holds a valid patent for Linagliptin in India until August 2023
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.